EGFR and cancer: For instance, EGFR were biased in PTPscore-high subgroups with mRNA alteration in eight cnacers (e.g., ACC, logFC = 1.42, FDR< 1.64 × 10-10; LGG, logFC = 1.50, FDR< 3.13 × 10-10), protein alteration in three cancers (e.g., CHOL, logFC = -1.34, FDR = 0.016; LGG, logFC = 0.83, FDR< 3.13 × 10-10), CNV alteration in two cancers (PAAD, FDR< 1.15× 10-10;LGG, FDR< 4.45× 10-12) and methylation alteration in nine cancers (e.g., LUAD, logFC = 0.18, FDR = 0.004; liver hepatocellular carcinoma (LIHC), logFC = 0.48, FDR< 2.55× 10-11).